AngioDynamics (ANGO) Misses Q1 EPS by 4c, Reaffirms FY18 Guidance

AngioDynamics (NASDAQ: ANGO) reported Q1 EPS of $0.12, $0.04 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $86.1 million.

The Company reaffirmed its FY2018 financial guidance of a net sales range of $352 to $359 million, adjusted earnings per share (EPS) of $0.64 to $0.68 and free cash flow of greater than $35 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery